Stimvia – a novel technology that enables safe, effective and non-invasive delivery of neuromodulation treatments
Who we are
We are Stimvia, a Czech technology company and a leader in non-invasive solutions for Overactive Bladder (OAB). We developed the URIS® system, a first-of-its-kind technology that uses the patented eTNM® neuromodulation method to target deep brain structures. Results show not only a significant benefit in managing OAB symptoms, but also promising potential for use in Parkinson’s disease.
Redefining the standard in the treatment of chronic diseases
What we do
We bring to market technology solutions based on targeted neuromodulation of the peripheral nerves and their connection with the central nervous system. We currently focus on stimulation of the peroneal nerve, whose functional links to the brain control centres play a key role in regulating urinary function. This approach is based on clinical evidence and represents one of the most promising directions in neuromodulation.
Our mission is to make clinically effective treatment of chronic diseases accessible without drugs, needles or invasive solutions.
Our product
The URIS® technology is a certified medical device under the MDR, approved by the prestigious TÜV SÜD institution. Thanks to its safety and ease of use, URIS® has the potential to become a new standard of care.
No more acting on sudden urges. Non-invasive. Painless.
- 90% of patients undergoing treatment achieve at least a 50% reduction in urgency urinary incontinence (UUI)
- 68% of patients undergoing treatment achieve full continence
Patients’ stories
URIS® changes the lives of people with chronic diseases without drugs and without surgery. It enables them to return to everyday activities and live without constant limitations. Read users’ experiences and see the impact of the technology in practice.
For investors
URIS® technology is a suitable option for up to 80% of indicated patients in whom pharmacotherapy has failed. At this stage, we are opening space for strategic cooperation aimed at fully developing the commercial and global potential of the technology. We have clinical validation, certification and real-world results behind us, and we operate in an area where Overactive Bladder represents a global market worth billions.
URIS® represents an investment opportunity in the neuromodulation segment, combining a rapidly growing market, strong clinical support and a scalable business model.
In Europe and the United States, we record up to 75 million OAB patients
For medical doctors
URIS® is a suitable option for patients with Overactive Bladder (OAB) in whom pharmacotherapy has failed and who do not wish to undergo invasive treatment. Our technology offers a balanced risk-benefit profile compared with other invasive methods.
Without needles or surgery and with a low risk of side effects, URIS® provides results comparable with invasive procedures. Clinical studies confirm that it is one of the most effective methods in the treatment of OAB.
Job offers
Would you like to take part in developing an innovative technology that improves patients’ lives? We are looking for experienced engineers as well as young talent who want to do things differently and help us change the world of healthcare. Contact us and join our team.
News
The most interesting articles, reports, clinical studies results and other materials about our URIS® technology.
